Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Browne IM, Andre F, Chandarlapaty S, Carey LA, et al. Lancet Oncol 2024;25:e139-e151.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Browne IM, Andre F, Chandarlapaty S, Carey LA, et al. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Lancet Oncol 2024;25:e139-e151.
PMID: 38547898